临床荟萃
• 专题 • 上一篇 下一篇
出版日期:
发布日期:
通讯作者:
作者简介:
Online:
Published:
Contact:
摘要： 霍奇金淋巴瘤（HL）是一种治愈率较高的恶性肿瘤，但临床上仍有少数病例会复发或难治。目前，挽救性化疗联合造血干细胞移植仍是难治复发HL的标准治疗，PET/CT扫描检测为难治复发病例及早调整治疗提供了评测手段。此外，难治复发HL的病理生理学研究进展为开发新型的靶向治疗提供了理论依据，并在早期临床试验中显示出良好应用前景。在这篇综述中，我们总结了难治复发HL的治疗策略和治疗选择。
关键词: 霍奇金病, 正电子发射断层显像术, 分子靶向治疗
Abstract: Although Hodgkin's lymphoma (HL) is highly curable， a minority of patients still presented as refractory to the frontline treatment or relapse after completion remission.For refractory or relapsed HL (rrHL)， salvage chemotherapy followed by hematopoietic stem cell transplantation remains the standard of care. PET/CT emerged as a valid measurement for response-adapted treatment strategies in rrHL. Moreover， recent knowledges on the pathophysiology of rrHL have promoted the development of novel targeted approach， some of that have shown promise in the early clinical trials.In this review， we summarize the current treatment strategies for rrHL.
Key words: hodgkin disease, positronemission tomography, molecular targeted therapy
陈永铨，杨婷. 难治复发霍奇金淋巴瘤的治疗选择[J]. 临床荟萃, doi: 10.3969/j.issn.1004-583X.2017.12.003.
Chen Yongquan， Yang Ting. Current treatment strategies for refractory/relapsed Hodgkin's lymphoma[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2017.12.003.
导出引用管理器 EndNote|Ris|BibTeX
链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2017.12.003
https://huicui.hebmu.edu.cn/CN/Y2017/V32/I12/1022
